Approval · Notice of Compliance 32829 · 2024
VRAYLAR: Notice of Compliance 32829
Issued March 6, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32829
- Date
- March 6, 2024
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To revise the current language in the Product Monograph (PM) related to the effectiveness of oral contraceptives taken during treatment with VRAYLAR.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| VRAYLAR | Not yet assigned | — |
Medicinal ingredients
- CARIPRAZINE HYDROCHLORIDE 1.5 MG per CAP
- CARIPRAZINE HYDROCHLORIDE 3 MG per CAP
- CARIPRAZINE HYDROCHLORIDE 4.5 MG per CAP
- CARIPRAZINE HYDROCHLORIDE 6 MG per CAP